MedTrace Logo

Bone Resorption, Osteoclastogenesis and Adalimumab

NCT00814866 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2016-10-27

No results posted yet for this study

Summary

Osteoclastic bone resorption depends on both the capacity to generate osteoclasts (osteoclastogenesis) and on individual osteoclast activity. The investigators objective is to study the effect of anti-TNF therapy on the number of osteoclast precursors in the peripheral blood of patients with Rheumatoid Arthritis, on in vitro osteoclastogenesis and on osteoclast activity before and during the treatment of patients with Rheumatoid Arthritis with Adalimumab.

Conditions

Interventions

DRUG

Adalimumab

Adalimumab 40 mg sub-cutaneously every two weeks

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Artur Fernandes, MD, PhD · Centre de recherche du Centre hospitalier universitaire de Sherbrooke

  • Gilles Boire, MD, M.Sc. · Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-09-30
Completion
2011-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00814866 on ClinicalTrials.gov